Prior to the current activities in LSTM, Andre Daher was the head of the clinical research division of Farmanguinhos/Fiocruz, a Federal governmental pharmaceutical industry in Rio de Janeiro, Brazil. He also used to coordinate two collaborative initiatives in clinical research at Fiocruz Vice Presidency of Research: The Clinical Research Platform for Technological Development in Public Health, and the Fiocruz Clinical Research Network.
He is a medical doctor specialized in Infectious Diseases by the Fluminense Federal University and in Clinical Research by the Oswaldo Cruz German Hospital/Brazilian Ministry of Health. Over the course of his career, he has gained expertise on technological development in pharmaceuticals and served as consultant for international networks. He is currently a consultant for clinical trials in malaria at the Brazilian Ministry of Health and a Scientific Advisory Committee member of the Drugs for Neglected Disease initiative.
1. New approaches to treat malaria vivax in Brazil. The evaluation of Artemisin-based Combination Therapies associated to primaquine during seven days to treat uncomplicated malaria vivax in Brazil is an innovative approach. Nevertheless, it is aligned to renowned infectious disease treatments’ trends: the use of multiple drugs in combination, a single treatment to all malaria species, and a patient friendly regimen.
2. Evaluation of P.vivax relapse rates in Brazil. The evaluation of the vivax epidemiology may shed light in the efficiency of the P.vivax radical treatment in Brazil (primaquine during seven days) and drive future field interventions or guidelines updates.